The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://tasneemkohq097525.wikimeglio.com/10335179/glp_3_retatrutide_a_comparative_analysis